Jeffrey M. Jonas - 03 Jan 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol: SAGE
Transactions as of: 03 Jan 2023
Net transactions value: +$71,604
Form type: 4
Filing time: 05 Jan 2023, 15:29:34 UTC
Previous filing: 16 Jun 2022
Next filing: 07 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Options Exercise	$71,604	+2,501	+2.2%	$28.63	118,308	03 Jan 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Options Exercise	$0	-2,501	-4.2%	$0.000000	57,499	03 Jan 2023	Common Stock	2,501	$28.63	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option vested in full on February 8, 2020.